According to, Endo Pharmaceuticals acquired Par Pharma for $8.05 billion. In the article, the CEO of Endo Pharmaceuticals says: “This transaction with Par builds upon our generics growth, adding a strong portfolio of high barrier-to-entry and attractive gross margin products while also transforming Endo, creating a powerful corporate platform for future growth and strategic M&A.” For more information, visit: